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ABSTRACT
Design Pharmacokinetic and pharmacodynamic
parameters of cremophor-paclitaxel, nab-paclitaxel
(human-albumin-bound paclitaxel, Abraxane) and a
novel mouse-albumin-bound paclitaxel (m-nab-paclitaxel)
were evaluated in genetically engineered mouse models
(GEMMs) by liquid chromatography-tandem mass
spectrometry (LC-MS/MS), histological and biochemical
analysis. Preclinical evaluation of m-nab-paclitaxel
included assessment by three-dimensional high-
resolution ultrasound and molecular analysis in a novel
secreted protein acidic and rich in cysteine (SPARC)-
deﬁcient GEMM of pancreatic ductal adenocarcinoma
(PDA).
Results nab-Paclitaxel exerted its antitumoural effects
in a dose-dependent manner and was associated with
less toxicity compared with cremophor-paclitaxel. SPARC
nullizygosity in a GEMM of PDA, KrasG12D;p53ﬂox/−;
p48Cre (KPfC), resulted in desmoplastic ductal pancreas
tumours with impaired collagen maturation. Paclitaxel
concentrations were signiﬁcantly decreased in SPARC
null plasma samples and tissues when administered as
low-dose m-nab-paclitaxel. At the maximally tolerated
dose, SPARC deﬁciency did not affect the intratumoural
paclitaxel concentration, stromal deposition and the
immediate therapeutic response.
Conclusions nab-Paclitaxel accumulates and acts in a
dose-dependent manner. The interaction of plasma
SPARC and albumin-bound drugs is observed at low
doses of nab-paclitaxel but is saturated at therapeutic
doses in murine tumours. Thus, this study provides
important information for future preclinical and clinical
trials in PDA using nab-paclitaxel in combination with
novel experimental and targeted agents.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDA) is consid-
ered one of the most aggressive and lethal human
malignancies with increasing incidence and a 5-year
survival rate of less than 5%.1 Over the past
decades, intensive efforts to develop novel targeted
therapies in combination with various chemothera-
pies have not yielded a signiﬁcant breakthrough,
and the standard of care chemotherapy has
remained gemcitabine despite only marginal effects
on patient survival.2 Oxaliplatin, irinotecan, leu-
covorin and 5-ﬂuorouracil (FOLFIRINOX) has
recently been reported to achieve a signiﬁcant
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Signiﬁcance of this study
What is already known about this subject
▸ Pancreatic ductal adenocarcinoma (PDA) is a
stroma-rich tumour that is highly refractory to
systemic therapies.
▸ nab-paclitaxel (Abraxane) alone and in
combination with gemcitabine has recently
shown signiﬁcant clinical activity in human and
murine PDA.
▸ Secreted protein acidic and rich in cysteine
(SPARC) has been proposed as a biomarker for
nab-paclitaxel-based chemotherapies by
sequestering nab-paclitaxel to concentrate the
drug intratumourally and to deplete tumour
stroma.
What are the new ﬁndings
▸ nab-paclitaxel acts in a dose-dependent but
SPARC saturable manner in genetically
engineered mouse models (GEMM).
▸ SPARC ablation in KPfC mice results in
desmoplastic ductal pancreas tumours with
impaired collagen maturation.
▸ A preclinical trial using a novel formulation of
mouse-nab-paclitaxel demonstrates robust
therapeutic effects independent of SPARC
expression.
▸ Prolonged treatment with mouse-nab-paclitaxel
does not lead to stromal depletion in the KPC
mouse model.
How might it impact on clinical practice in
the foreseeable future
▸ nab-paclitaxel could be investigated with
additional stromal depletion agents to
maximise treatment effects.
▸ Preclinical platforms using
mouse-nab-paclitaxel can be employed to
identify more powerful combination therapies
for early clinical testing.
▸ SPARC serum levels should be measured in
PDA patients prior to starting
nab-paclitaxel-based chemotherapies to
determine whether high plasma SPARC levels
affect plasma pharmacokinetics of albumin
formulated drugs.
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survival beneﬁt for patients with metastatic PDA compared with
gemcitabine (11.1 vs 6.8 months); however, increased rates of
toxicity will likely limit the frequent clinical use of this regimen
in PDA patients.3 Histologically, PDA is characterised by abun-
dant tumour stroma with activated cancer-associated ﬁbroblasts
(CAFs) and immune cells that contribute to a dense and highly
dynamic tumour microenvironment (TME) around neoplastic
ductal cells.4 The distinct stromal architecture has increasingly
been appreciated to create physical barriers for drug delivery
and also to provide additional biochemical signals that collect-
ively promote the resistance of PDA cells to systemic and tar-
geted therapies.5–13 Secreted protein acidic and rich in cysteine
(SPARC/osteonectin/BM40) is an albumin-binding 42-kDa
matricellular glycoprotein that has recently gained signiﬁcant
clinical interest as a potential biomarker in PDA. Indeed,
SPARC is overexpressed by ﬁbroblasts in the TME of human
PDA and has been shown to inversely correlate with survival.14
15 A novel drug formulation of paclitaxel bound to albumin
(nab-paclitaxel, Abraxane) has been hypothesised to accumulate
in and potentially deplete PDA tumour stroma via binding of
albumin to SPARC.16 A phase I/II trial of gemcitabine in com-
bination with nab-paclitaxel showed promising overall survival
rates and suggested the potential usefulness of SPARC as a pre-
dictive biomarker.17 More recently, results from the ﬁrst rando-
mised phase III study of nab-paclitaxel and gemcitabine
Metastatic Pancreatic Adenocarcinoma Clinical Trial, MPACT)
have conﬁrmed initial observations of clinical beneﬁt and
showed a signiﬁcant median survival improvement over gemcita-
bine monotherapy (8.5 vs 6.7 months) in patients with meta-
static PDA.18 In parallel, our laboratory has conﬁrmed the
antitumour efﬁcacy of nab-paclitaxel and gemcitabine and dis-
covered a synergistic drug–drug interaction where nab-paclitaxel
impaired gemcitabine metabolism due to reactive oxygen species
(ROS)-mediated degradation of cytidine deaminase.19 Following
this encouraging data, nab-paclitaxel plus gemcitabine is cur-
rently being evaluated for registration as novel ﬁrst-line treat-
ment for PDA patients. Furthermore, a recent phase II study
found preliminary activity of nab-paclitaxel monotherapy in
patients who progressed on gemcitabine-based therapy.20
The use of biomarkers to select effective targeted and cyto-
toxic therapies and predict response to treatment for individuals
(‘personalised medicine’) is becoming a reality in certain types
of cancer but has remained elusive in PDA. Recent clinical data
suggested that expression of SPARC in the stroma of archived
tumour tissue could predict for response to nab-paclitaxel and
gemcitabine,17 and a detailed analysis of tumour specimen from
the MPACT study is still pending. Preclinical and clinical data
on the potential of stromal SPARC to determine treatment
response to nab-paclitaxel, sequester nab-paclitaxel to concen-
trate the drug intratumourally, and to deplete tumour stroma
have been conﬂicting in different tumour entities and hampered
by methodological differences.20–23 A preclinical study in
patient-derived xenografts reported stromal depletion upon nab-
paclitaxel treatment,17 whereas our own results in a genetically
engineered mouse model (GEMM) of PDA did not indicate
such effects following short-term treatment with nab-
paclitaxel.19 A limitation of our prior study was anaphylaxis due
to the use of human-albumin-bound paclitaxel, and thus, did
not allow us to investigate longer term treatment effects such as
stromal depletion.19 Furthermore, the interaction of murine
SPARC and human albumin does not recapitulate the genuine
biological situation and may possibly bias the results.
Here, we determine the pharmacokinetic and pharmacody-
namic proﬁle of nab-paclitaxel in murine PDA in vivo and
assess the preclinical effectiveness in GEMMs of PDA in a
SPARC-dependent manner by using a novel experimental
mouse-albumin paclitaxel (m-nab-paclitaxel) that was speciﬁc-
ally formulated for this purpose. Thus, our study provides
important information for future preclinical and clinical trials in
PDA using nab-paclitaxel in combination with novel experimen-
tal and targeted agents.
MATERIALS AND METHODS
Additional details are provided in online supplementary materi-
als and methods.
Genetically engineered mice
The following genetically engineered mice were used for this study:
SPARC−/− mice (B6;129S-Sparctm1Hwe/J) were purchased from
Charles River (Margate, UK).24 LSL-KrasG12D/+;LSL-Trp53R172H/+;
Pdx-1-Cre (KPC) and KrasG12D/+;Trp53ﬂox/−;p48-Cre (KPfC) mice
were used for the experiments, and both models develop advanced
and metastatic PDAwith 100% penetrance at an early age recapitu-
lating the full spectrum of histopathological and clinical features of
human PDA.25 Mice were housed at a 12-h light, 12-h dark cycle.
All procedures were conducted in accordance with the institutional
and national guidelines.
Drugs
nab-paclitaxel (Abraxane) and mouse (m)-nab-paclitaxel were for-
mulated and provided by Celgene Corporation (USA) and resus-
pended in sterile normal saline at 24 mg/mL, 12 mg/mL or 6 mg/
mL, and intravenously administered at 120 mg/kg, 60 mg/kg or
30 mg/kg. Paclitaxel was provided by Addenbrooke’s Hospital
Pharmacy (Cambridge, UK), resuspended in Cremophor at 6 mg/
mL or 2 mg/mL and administered at 10 mg/kg or 30 mg/kg. The
amount of paclitaxel is equal in 30 mg/kg nab-paclitaxel and 30 mg/
kg cremophor-paclitaxel; 60 mg/kg nab-paclitaxel in mice corre-
sponds to approximately 180 mg/m2 nab-paclitaxel in humans.26
LC-MS/MS of paclitaxel
Fresh frozen tumour samples from different time points were pro-
cessed and analysed for paclitaxel concentrations using liquid
chromatography tandem mass spectrometry (LC-MS/MS). Brieﬂy,
samples were extracted with 100% acetonitrile containing
2H5-paclitaxel as internal standard, and chromatography was done
on an acquity ultra performance liquid chromatography (UPLC),
high strength silica (HSS) T3 50 mm×2.1 mm id., 1.8 mm column
(Waters, Hertfordshire, UK). The mobile phase was (A) 0.1%
acetic acid: (acetonitrile:methanol (1:1)) 70:30 and (B) 0.1%
acetic acid: (acetonitrile:methanol (1:1)) 10:90. The gradient, at a
ﬂow rate of 0.3 mL/min, was 100% A for 0.6 min changed to over
0.2 min to 100% B and maintained for 2 min, changed back to
100% A over 0.2 min and held for 1.5 min to give a total run time
of 4.5 min. LC-MS/MS was performed on a triple stage quadru-
pole (TSQ) Vantage mass spectrometer (Thermo Scientiﬁc,
Waltham, MA) ﬁtted with a heated electrospray ionisation
(HESI-II) probe operated in positive mode at a spray voltage of
5 KV and capillary temperature of 350°C. Quantitation was done
by multiple reaction monitoring of the transitions 876.4–308.1
and 881.4–308.1 for paclitaxel and the internal standard, respect-
ively, and data acquisition was done using LC Quan2.5.6 (Thermo
Fisher Scientiﬁc, Waltham, MA).
Therapeutic intervention studies with m-nab-paclitaxel
Following weekly manual palpation from 2 months of age, KPC
and KPfC mice were subjected to high-contrast ultrasound screen-
ing using the Vevo 2100 System with a MS250, 13–24MHz
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scanhead (Visual Sonics, Inc, Amsterdam, NL). Mice with tumour
diameters of 5–9 mm were randomised and enrolled into the
therapeutic intervention studies: m-nab-paclitaxel was intraven-
ously administered at 60 mg/kg in tumour-bearing mice according
to the outlined treatment schedules. During the study, tumour
growth was quantiﬁed on day 3 and day 7 by measuring tumour
volumes using reconstructed three-dimensional (3D) ultrasonog-
raphy with the integrated Vevo 2100 software package. The last
administration of m-nab-paclitaxel was given 2 h prior to
endpoint.
Western blot analysis
Western blots were performed as previously described.27 The
following primary antibodies were used: Hsp90 (Cell Signaling)
and murine SPARC (R&D Systems). Membranes were incubated
with secondary HRP-antibodies ( Jackson ImmunoResearch) and
developed using the enhanced chemiluminescence (ECL) detec-
tion system (GE Healthcare).
Histological examination
Tissues were ﬁxed in 10% neutral buffered formalin for 24 h and
transferred to 70% ethanol. Tissues were embedded in parafﬁn,
and 3–5 mm sections were processed for H&E staining, Herovici
(Sigma) and immunohistochemistry using standard protocols as
previously described.10 The following antibodies were used:
murine SPARC (R&D Systems, AF942), Cleaved Caspase-3 (Cell
Signaling Technology, 9661), CD31 (BD Pharmingen, 553370),
Ki-67 (Dako, M7249) and phospho-histone-3 (Upstate, 06-570).
Images were acquired on an Olympus BX51 microscope
(Olympus) or Aperio XT automated scanning system and
Imagescope 10 software (Leica). More information can be found
in online supplementary material and methods.
Statistical analysis
Statistical analysis was carried out using GraphPad Prism V.5.01
(GraphPad Software). The Mann–Whitney non-parametric t test
was used and results are presented as mean±SE. p<0.05 was
considered to be signiﬁcant.
RESULTS
Pharmacokinetics and pharmacodynamics of
cremophor-paclitaxel and nab-paclitaxel in KPC tumours
SPARC is overexpressed in the pancreatic tumour microenviron-
ment in KPC mice,19 predominantly by cancer-associated ﬁbro-
blasts, and to a lesser extent in tumour cell lines (see online
supplementary ﬁgure 1A). Since this expression pattern is
similar to that described with PDA patients,14 15 this mouse
model represents a tractable experimental platform to interro-
gate the interaction of SPARC and nab-paclitaxel.
To systematically compare pharmacokinetics and pharmaco-
dynamics of nab-paclitaxel and cremophor-paclitaxel, tumour-
bearing KPC mice were intravenously administered a single dose
of equimolar (30 mg/kg) cremophor-paclitaxel (n=12), nab-
paclitaxel (n=5) and equitoxic 120 mg/kg nab-paclitaxel (n=10).
Notably, 5/12 mice (43%) experienced acute toxicity-related
health issues with physical inactivity, loss of body temperature and
respiratory distress following the administration of 30 mg/kg
cremophor-paclitaxel, and those mice had to be culled prior to the
deﬁned endpoint. In contrast, 120 mg/kg nab-paclitaxel was well
tolerated in all 10 mice treated. Tissues were collected 4 h post-
dose and assessed for intratumoural paclitaxel concentrations by
LC-MS/MS and pharmacodynamic parameters by immunohisto-
chemistry. Strikingly, equimolar doses of cremophor-paclitaxel and
nab-paclitaxel (30 mg/kg) resulted in similar intratumoural
paclitaxel concentrations (mean: 6.9 ng/mg, SD:±4.5 vs 4.3 ng/
mg±1.75, p=0.28, ﬁgure 1A), suggesting that intratumoural pacli-
taxel delivery was independent of the albumin nanoformulation.
The maximum tolerated dose (MTD) of 120 mg/kg nab-paclitaxel
resulted in approximately fourfold higher paclitaxel levels
(30.8 ng/mg±10.4, ﬁgure 1A), indicating a nearly linear intratu-
moural accumulation of nab-paclitaxel with signiﬁcantly less acute
systemic toxicity compared with 30 mg/kg cremophor–paclitaxel.
Paclitaxel has been shown to elicit its antitumoural effects
through induction of apoptosis and cell cycle arrest in G2-M. We
therefore assessed the effects of the different dosing regimens in
KPC tumours by immunohistochemistry for proliferation marker
ki-67, apoptosis marker cleaved caspase 3 (CC3) and phosphory-
lated histone H3 (pH3) as a marker for aberrant mitotic ﬁgures. At
the MTD of 120 mg/kg, nab-paclitaxel induced signiﬁcant levels of
apoptosis compared with untreated (p<0.001), cremophor-
paclitaxel (p<0.001) and low-dose nab-paclitaxel (p<0.01) treated
tumours (ﬁgure 1B). Notably, cremophor-paclitaxel and low-dose
nab-paclitaxel had no signiﬁcant effects on tumour cell death com-
pared with untreated controls. The appearance of aberrant mitotic
ﬁgures that contained an abundance of phosphorylated histone H3
was increased following treatment with cremophor-paclitaxel,
low-dose nab-paclitaxel and most signiﬁcantly, in the 120 mg/kg
nab-paclitaxel cohort (ﬁgure 1C, p<0.001). Again, equimolar
doses of nab-paclitaxel and cremophor-paclitaxel did not show sig-
niﬁcant differences in the percentage of pH3-positive cells
(p=0.15, ﬁgure 1C). nab-Paclitaxel and cremophor-paclitaxel
decreased overall proliferation rate of KPC tumours marginally, and
although we found a signiﬁcant difference in tumour proliferation
between low-dose and high-dose nab-paclitaxel (p<0.02), compari-
son against untreated KPC tumours failed to reach signiﬁcance
(ﬁgure 1D; p=0.09).
Overall, these results suggest that nab-paclitaxel and
cremophor-paclitaxel have comparable pharmacokinetic and
pharmacodynamic properties in murine pancreas tumours with
endogenous SPARC expression. However, nab-paclitaxel can be
dosed at least four times higher than cremophor-paclitaxel due
to improved tolerability and therefore exerts signiﬁcantly better
antitumoural effects in vivo.
m-nab-Paclitaxel extended intervention study in the KPC
mouse model
nab-Paclitaxel is formulated with human albumin and thus causes
fatal anaphylactic reactions in mice following repeated intravenous
injections.19 Therefore, mechanisms such as stromal depletion that
require longer term follow-up and repeated injections could not
be properly investigated in the past. In order to circumvent these
issues, we preclinically assessed a novel, mouse albumin-bound
paclitaxel that was speciﬁcally formulated for experimental pur-
poses and termed murine (m)-nab-paclitaxel. First, we compared
the bioavailability of 30 mg/kg nab-paclitaxel (n=5) and 30 mg/kg
m-nab-paclitaxel (n=5) in healthy C57B6 wild-type mice and
demonstrated that plasma and tissue concentrations of paclitaxel
were comparable between the two compounds following i.v.
administration (see online supplementary ﬁgure 2A,B).
We then determined that 60 mg/kg q3d m-nab-paclitaxel was
the MTD in wild-type mice when weight loss became apparent
on day 15 (data not shown). To assess whether this dose of
m-nab-paclitaxel depletes tumour stroma in KPC mice, tumour-
bearing mice (tumour diameter 5–9 mm by 3D ultrasound)
were identiﬁed and treated over the course of 15 days (see
online supplementary ﬁgure 2C). Immunohistochemical analyses
demonstrated that treatment with m-nab-paclitaxel signiﬁcantly
increased the number of aberrant mitotic ﬁgures that contained
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an abundance of phosphorylated histone H3 compared with
untreated KPC tumours (ﬁgure 2A, p<0.001). Furthermore,
m-nab-paclitaxel signiﬁcantly increased the number of apoptotic
neoplastic cells while sparing stromal ﬁbroblasts in the tumour
(ﬁgure 2B, p<0.001). Histological examination of the tumour
stroma showed that there was no difference in stromal depos-
ition or SPARC expression following m-nab-paclitaxel adminis-
tration (ﬁgure 2C). Although we cannot exclude the possibility
that further prolongation of treatment may affect the stromal
compartment, it is worth noting that stromal depletion in
patient-derived xenografts required only ﬁve doses of nab-
paclitaxel.17 Taken together, our results suggest that extended
treatment with 60 mg/kg m-nab-paclitaxel is well tolerated for
15 days and elicits substantial neoplastic cell death while sparing
the stromal compartment in KPC tumours.
SPARC-dependent pharmacokinetics of m-nab-paclitaxel
To investigate the potential interaction between the albumin-
binding protein SPARC and m-nab-paclitaxel in SPARC-deﬁcient
mice, a pharmacokinetic tissue uptake study was undertaken. In
C57B6 wild-type mice, SPARC can be predominantly detected in
plasma (n=7) and testis tissue (n=2), whereas kidney (n=2),
liver (n=2) and normal pancreas tissues (n=2) show very low or
undetectable levels of SPARC protein (see online supplementary
ﬁgure 3A,B). Paclitaxel concentrations were measured in plasma,
kidney and testis samples at seven different time points (0.5 h,
1 h, 2 h, 4 h, 8 h, 20 h and 48 h) in SPARC+/+ (n≥3 mice per
time point, n=30 in total) and SPARC−/− mice (n≥3 mice per
time point, n=31) following a single intravenous injection of
30 mg/kg m-nab-paclitaxel. Strikingly, the initial phase of pacli-
taxel distribution from the blood circulation to peripheral com-
partments (alpha phase) was delayed in SPARC+/+ mice
compared with SPARC−/− mice (ﬁgure 3A). Plasma paclitaxel
levels were signiﬁcantly increased after 1 h (p<0.01) and 2 h
(p<0.02) postinjection of m-nab-paclitaxel, and plasma paclitaxel
area under the curve (AUC) was increased by 61.7% in SPARC+/+
versus SPARC−/− (24 100 ng h/mL vs 14 900 ng h/mL)
(ﬁgure 3A). Accordingly, paclitaxel concentrations were also
Figure 1 Single-dose pharmacokinetic and pharmacodynamic analysis of cremophor-paclitaxel and nab-paclitaxel in KPC tumours
(A) Tumour-bearing KPC mice were treated with a single dose of cremophor-paclitaxel (30 mg/kg), nab-paclitaxel at 30 mg/kg or nab-paclitaxel at
120 mg/kg. Tumour tissues were harvested and assessed for intratumoural paclitaxel levels 4 h later by liquid chromatography tandem mass
spectrometry (LC-MS/MS) (n≥5; *p=0.001; ** p<0.001). (B) Automated quantiﬁcation of 30 randomly chosen ﬁelds for cleaved caspase-3
(CC3, *p<0.01), (C) phospho-histone H3 (*p<0.02) and (D) ki67 proliferation (*p<0.02) immunohistochemistry. Cremophor-paclitaxel LC-MS/MS
results from ﬁgure 1A have been previously published by Frese et al.19
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found to be increased in SPARC+/+ kidney and testis tissue at 1 h
(p<0.01) and 2 h (p<0.005) compared with SPARC−/−. The
AUC was increased by 18.3% (218.4 vs 184.5 ng h/mL) for
kidney, and only marginally increased by 2.7% (70.8 vs
68.9 ng h/mL) in testis tissue (ﬁgure 3B,C). Notably, the pacli-
taxel AUC increase in kidney and testis did not correlate with
SPARC expression as SPARC is only expressed in testis but not in
kidneys of SPARC+/+ mice (see online supplementary ﬁgure 3A).
Importantly, SPARC expression in testis tissue did not affect the
mean vessel density (see online supplementary ﬁgure 3C), and
therefore cannot explain the increased AUC. Since kidney and
testis samples were not terminally perfused with saline prior to
analysis, we hypothesise that increased paclitaxel concentrations
in SPARC+/+ organs are caused by higher quantities of blood-
borne paclitaxel.
To investigate whether SPARC deﬁciency accounts for differ-
ences in paclitaxel clearance, we treated SPARC+/+ (n=20) and
SPARC−/− mice (n=20) with low-dose cremophor-paclitaxel
(10 mg/kg) at four different time points (0.5 h, 1 h, 2 h and 4 h,
n=5 per time point) and detected identical plasma paclitaxel
concentrations (ﬁgure 3D), suggesting that the increased levels
of nab-paclitaxel do not stem from altered paclitaxel metabolism
Figure 2 m-nab-Paclitaxel extended (ﬁve doses) intervention study in the KPC model. (A) Automated quantiﬁcation of 30 randomly chosen ﬁelds
for phospho-histone H3 and (B) cleaved caspase-3 immunohistochemistry (*p<0.001) following treatment with 60 mg/kg every 3 days for ﬁve doses
(q3d×5) m-nab-paclitaxel and compared with untreated (UNtx) KPC tumours. (C) Representative H&E stainings from untreated versus long-term
m-nab-paclitaxel-treated KPC tumours show no relevant stromal collapse or differences in secreted protein acidic and rich in cysteine expression.
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but are due to a speciﬁc interaction between the albumin formu-
lation of paclitaxel and circulating or endothelial SPARC.
SPARC-deﬁcient GEMM of PDA (KPfC SPARC−/−) develop
pancreas tumours with impaired collagen maturation
Since SPARC has been hypothesised to sequester albumin-bound
drugs such as nab-paclitaxel and thereby concentrate the drug
intratumourally, we sought to generate a GEMM with genetic-
ally ablated SPARC to provide an experimental platform for pre-
clinical investigations.
KrasLSL-G12D;p53ﬂox/+;p48Cre (KPfC) mice were generated
and developed metastatic PDA with a latency and pathophysio-
logical characteristics indistinguishable from the classic KPC
model. The KPfC mice were interbred with SPARC−/− mice to
generate cohorts that were SPARC+/+ (n=10), SPARC+/−
(n=18) or SPARC−/− (n=10) and monitored for pancreatic
tumour development from 2 months of age by weekly manual
palpation. SPARC expression did not affect tumour incidence
and latency, and pancreatic tumour onset was comparable
among the cohorts (SPARC+/+, mean: 154 days; SPARC+/−,
153 days; SPARC−/− 156 days; range 67–209 days, ﬁgure 4A).
Also, genetic SPARC ablation did not affect the histological
appearance of tumours and resulted in murine ductal adenocar-
cinoma with desmoplastic features indistinguishable from the
traditional KPC model (ﬁgure 4B). Overall proliferation rate
and mean vessel density as assessed by Ki67 and CD31 immu-
nohistochemistry did not show signiﬁcant differences dependent
on the SPARC status (see online supplementary ﬁgure 4A,B).
Interestingly, detailed histological analysis of the extracellular
matrix composition revealed impaired collagen maturation in
KPfC SPARC−/− mice as evidenced by Herovici stains (ﬁgure
4B), supporting the role of SPARC in collagen production and
turnover.28 Following pancreatic tumour development, systemic
disease such as haemorrhagic ascites, cachexia and widespread
liver metastases was observed in the majority of mice. At end-
point, the metastatic tumour burden in the liver did not signiﬁ-
cantly differ depending on the SPARC status (ﬁgure 4C).
SPARC-dependent pharmacokinetics and pharmacodynamics
of m-nab-paclitaxel in the KPfC mouse model
To test whether the intratumoural accumulation of m-nab-
paclitaxel is dependent upon the expression of SPARC, we
administered m-nab-paclitaxel at therapeutic doses (60 mg/kg)
to KPfC SPARC−/− (n=11) and KPfC SPARC+/+ (n=8) mice
with established tumours of comparable size. Paclitaxel concen-
trations were measured in tumour biopsies, plasma and kidney
samples. Surprisingly, paclitaxel concentrations did not signiﬁ-
cantly differ between SPARC+/+ and SPARC−/− pancreatic
tumours, plasma and kidney samples 2 h after dosing (ﬁgure 5A,
see online supplementary ﬁgure 5A,B), indicating that neither
Figure 3 Secreted protein acidic and rich in cysteine (SPARC)-dependent pharmacokinetics of m-nab-paclitaxel. (A–C) Cohorts of SPARC−/− and
SPARC+/+ mice were treated with a single dose of 30 mg/kg m-nab-paclitaxel, and plasma, kidney and testis samples were harvested at seven
different time points (0.5 h, 1 h, 2 h, 4 h, 8 h, 20 h and 48 h) in SPARC+/+ (n≥3 mice per time point, n=30 in total) and SPARC−/− mice (n≥3 mice
per time point, n=31) and analysed by liquid chromatography tandem mass spectrometry (LC-MS/MS) (*p<0.02). (D) Cohorts of SPARC−/− (n=20)
and SPARC+/+ (n=20) mice were treated with 10 mg/kg cremophor-paclitaxel and plasma samples were analysed by LC-MS/MS for paclitaxel at four
different time points (0.5 h; 1 h; 2 h and 4 h; n=5 mice for each time point).
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Figure 4 Secreted protein acidic and
rich in cysteine (SPARC) deﬁcient
genetically engineered mouse model
(GEMM) of pancreatic ductal
adenocarcinoma develop pancreas
tumours with impaired collagen
maturation. (A) Tumour incidence
following weekly manual palpation of
KPfC mice from 2 months of age.
(B) Representative H&E from KPfC
SPARC+/+ and KPfC SPARC−/−mice
shows desmoplastic ducal
adenocarcinoma (upper panel).
Immunohistochemistry for SPARC
conﬁrms genetic ablation of SPARC
(middle panel), and Herovici stains
show decrease in mature collagen
ﬁbres (pink) in KPfC SPARC−/− mice
(lower panel). (C) Quantiﬁcation of ﬁve
serial liver sections (100 mm apart)
shows no signiﬁcant difference in
metastatic burden upon SPARC
heterozygous or homozygous deletion
in KPfC mice.
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circulating nor tumoural SPARC sequesters nab-paclitaxel to
accumulate the drug intratumourally during this timeframe.
Furthermore, we conducted a short-term intervention study that
compared the tumour growth in KPfC SPARC+/+ (n=6) and
KPfC SPARC−/− mice (n=5) with 60 mg/kg m-nab-paclitaxel
dosed 3× over 7 days (ﬁgure 5B, see online supplementary ﬁgure
5C,D). Final tumour volumes in KPfC SPARC+/+ versus KPfC
SPARC−/− mice did not signiﬁcantly differ from each other fol-
lowing 7 days of 60 mg/kg m-nab-paclitaxel treatment (mean:
152 mm3±43 vs 193 mm3±27; ﬁgure 5C). In line with treat-
ment responses observed by 3D ultrasound, levels of intratu-
moural apoptosis were not signiﬁcantly different in KPfC
SPARC+/+ and KPfC SPARC−/− pancreatic tumours (ﬁgure 5D).
Furthermore, weight loss (not shown) or hematological toxicity
was not affected by the SPARC status upon m-nab-paclitaxel
treatment (see online supplementary ﬁgure 5E). In summary, our
data suggest that although m-nab-paclitaxel exerts signiﬁcant
antitumour effects at 60 mg/kg by induction of apoptotic cell
death, drug delivery and response to treatment are independent
of SPARC expression.
DISCUSSION
Nanoparticle albumin-bound (nab)-paclitaxel, an albumin-
bound-stabilised paclitaxel formulation, has recently demon-
strated signiﬁcant improvements in median survival of patients
with metastatic PDA when combined with gemcitabine.18 Since
this drug combination represents the ﬁrst therapeutic regimen
that signiﬁcantly extends survival of advanced stage PDA
patients and is accompanied by an acceptable toxicity proﬁle,
nab-paclitaxel and gemcitabine will likely become the new
standard of care chemotherapy and will shortly be implemented
in national and international PDA treatment guidelines. Apart
from the striking antitumour effect of nab-paclitaxel alone in
KPC tumours, our group previously discovered a potential syn-
ergistic drug–drug interaction of gemcitabine and nab-paclitaxel
due to ROS-mediated degradation of cytidine deaminase that
resulted in higher levels of activated intratumoural gemcitabine
metabolites.19 However, the limited availability of patient tissue
and the lack of murine albumin-bound paclitaxel have hampered
our ability to address the mechanism of action of nab-paclitaxel
in human and murine PDA. Importantly, preliminary data
Figure 5 Pharmacokinetics and pharmacodynamics of m-nab-paclitaxel in the KPfC secreted protein acidic and rich in cysteine (SPARC) mouse
model. (A) Cohorts of KPfC SPARC+/+ (n=8) and KPC SPARC−/− mice (n=11) were treated with 60 mg/kg m-nab-paclitaxel, and tumour samples
were taken 2 h after dosing and analysed by liquid chromatography tandem mass spectrometry (LC-MS/MS). (B) Representative high-resolution
ultrasound picture of typical KPfC murine pancreatic tumour. (C) Quantiﬁcation of tumour volume growth using biweekly three-dimensional
high-resolution ultrasound shows no signiﬁcant decrease in tumour burden on day 7 in KPfC SPARC+/+ versus KPfC SPARC−/− pancreatic tumours
following three injections of 60 mg/kg m-nab-paclitaxel over 7 days. (D) Computer-based quantiﬁcation of apoptosis (cleaved caspase-3) in
pancreatic tumours from KPfC SPARC+/+ (n=6) and KPfC SPARC−/− mice (n=5) treated with 60 mg/kg m-nab-paclitaxel. All animals were sacriﬁced
2 h after the last dose of m-nab-paclitaxel.
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suggest that SPARC may play a pivotal role as a biomarker for
nab-paclitaxel-based chemotherapeutic regimens and may
predict responses to treatment.17
Our results suggest that intratumoural concentrations of pacli-
taxel following either nab-paclitaxel or cremophor-paclitaxel are
comparable in vivo; however, the dramatically reduced toxicity of
water-soluble nab-paclitaxel increases the maximum tolerated pacli-
taxel dose more than fourfold, thus resulting in signiﬁcantly higher
neoplastic cell death rates compared with cremophor-paclitaxel.
To determine whether SPARC would sequester nab-paclitaxel
to concentrate the drug intratumourally, we employed two
approaches. First, we used equimolar doses of nab-paclitaxel
and cremophor-paclitaxel in the KPC model with endogenous
SPARC expression and assessed intratumoural paclitaxel concen-
trations by LC-MS/MS. Second, we genetically ablated SPARC
in the closely related KPfC mouse model and used a novel
mouse albumin-bound paclitaxel formulation to account for
interspecies differences of human albumin and murine SPARC.
Both approaches showed that SPARC plays no role in sequester-
ing nab-paclitaxel intratumourally. Despite reports that SPARC
is associated with poor survival in PDA patients14 15 and that
pancreatic tumours grown orthotopically in SPARC−/− mice are
more metastatic and less vascular,29 SPARC deﬁciency did not
change the kinetics of tumour onset, growth rate, angiogenesis
and metastasis in the KPfC model in our study. However, exten-
sive pharmacokinetic analysis in SPARC+/+ and SPARC−/− mice
revealed a SPARC-speciﬁc distribution pattern of low-dose
m-nab-paclitaxel that was independent from paclitaxel metabol-
ism and saturable at higher concentrations of nab-paclitaxel in
tumour-bearing mice. Notably, increased paclitaxel concentra-
tions were observed in plasma and point towards a potential
interaction between circulating SPARC and albumin-bound
drugs. Alternatively, SPARC has also been shown to be
expressed in vascular endothelial cells and platelets,30–32 and
has frequently been implicated in the modulation of vascular
biology such as endothelial cell proliferation as well as pericyte
recruitment and regulation.33–35 It has been previously reported
in vitro that endothelial binding and transcytosis of albumin and
nab-paclitaxel may be mediated by endothelial cells that express
SPARC and other albumin-binding proteins such as gp60.16 36
However, using therapeutic concentration of m-nab-paclitaxel
(60 mg/kg) in tumour-bearing KPfC mice with genetically
ablated SPARC, this effect was saturable and both plasma and
intratumoural paclitaxel concentration did not show signiﬁcant
differences in the context of SPARC expression. Also, PDA neo-
plastic cell apoptosis and tumour volume increases following
treatment with m-nab-paclitaxel for 1 week were not substan-
tially affected by SPARC deletion. Therefore, we conclude that
although circulating SPARC may directly or indirectly increase
the intravascular concentration of low-dose nab-paclitaxel,
stromal-derived SPARC does not strongly inﬂuence the accumu-
lation of nab-paclitaxel intratumourally in a PDA mouse model.
However, we cannot exclude the possibility that extremely high
tissue or plasma SPARC concentrations in PDA patients may
increase drug concentrations and improve antitumour efﬁcacy,
and therefore, the measurement of SPARC plasma levels prior
to the initiation of nab-paclitaxel–based chemotherapies should
be investigated in pancreatic cancer trials.
Lastly, we examined whether prolonged treatment with
m-nab-paclitaxel was able to deplete tumour stroma in KPC
mice. Previous work from our group has shown that the exten-
sive desmoplastic reaction of endogenous murine pancreatic
tumours can be successfully depleted following 10–14 days of
continuous pharmacological inhibition of the sonic hedgehog
pathway by IPI-926.10 Therefore, and due to increasing toxicity
beyond 2 weeks, we chose to treat tumour-bearing KPC mice
over 2 weeks with m-nab-paclitaxel. In contrast to previous data
published in patient-derived xenografts,17 we found that
m-nab-paclitaxel predominantly induced apoptotic cell death in
tumour rather than stromal cells, and the stromal content of
desmoplastic murine pancreatic tumours was unchanged follow-
ing 2 weeks of treatment. This ﬁnding should prompt the design
of clinical trials that combine nab-paclitaxel with other stromal
altering agents such as PEGPH20 (hyaluronidase) to increase
intratumoural delivery of nab-paclitaxel.5–12
In conclusion, we present a pharmacokinetic and pharmaco-
dynamic analysis of cremophor-paclitaxel, nab-paclitaxel and a
novel m-nab-paclitaxel in various GEMMs of PDA that has
potential value for future preclinical and clinical drug develop-
ment. We found that nab-paclitaxel accumulation and antitu-
mour effects were dose-dependent, but SPARC independent in
GEMMs of PDA. Although stromal-derived SPARC may not
increase drug accumulation or induce stromal depletion upon
nab-paclitaxel treatment in our model system, plasma SPARC
levels may play a role in drug retention and therefore tissue
delivery in patients with baseline elevated SPARC levels. Future
clinical studies will be required to evaluate the potential value
of plasma SPARC as a non-invasive and predictive biomarker
for nab-paclitaxel-based chemotherapeutic regimens.
Acknowledgements We thank Manuel Hidalgo for sharing his data before
publication. We thank Dr. Aarthi Gopinathan for reviewing ultrasound scans. We
thank Frances Connor, Paul Mackin, Lisa Young and Steven Kupczak for
maintenance and management of mouse colonies, as well as staff from the
Cambridge Research Institute Biological Resource Unit, histology core and
pharmacokinetics core.
Contributors AN, KKF and DAT conceived and designed the experiments. AN, KKF
and DSC performed animal experiments. AN and KKF performed cell culture
experiments. AN, DSC, WJH and VE performed histology stainings. TEB, FMR and
DIJ designed and carried out paclitaxel pharmacokinetic experiments. AN and DAT
wrote the manuscript. All authors reviewed the manuscript.
Funding This research was supported by the University of Cambridge and Cancer
Research UK, The Li Ka Shing Foundation and Hutchison Whampoa Limited and the
National Institute for Health Research Cambridge Biomedical Research Centre. KKF
and DAT were supported by the European Community Grant EPC-TM-Net 256974.
AN was supported by the Deutsche Krebshilfe Mildred Scheel Postdoctoral
Fellowship. DIJ is a Group Leader in the Cancer Research UK Cambridge Institute.
TEB and FMR are supported by Cancer Research UK. DAT is also supported by the
Lustgarten Foundation for Pancreatic Cancer Research and by the Cold Spring
Harbor Laboratory Association.
Competing interests nab-Paclitaxel and m-nab-paclitaxel were formulated and
provided by Celgene Corporation.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/3.0/
REFERENCES
1 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin
2013;63:11–30.
2 Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical
beneﬁt with gemcitabine as ﬁrst-line therapy for patients with advanced pancreas
cancer: a randomized trial. J Clin Oncol 1997;15:2403–13.
3 Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med 2011;364:1817–25.
4 Neesse A, Michl P, Frese KK, et al. Stromal biology and therapy in pancreatic
cancer. Gut 2011;60:861–8.
5 Beatty GLChiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show
efﬁcacy against pancreatic carcinoma in mice and humans. Science 2011;331:1612–16.
6 Clark CE, Hingorani SR, Mick R, et al. Dynamics of the immune reaction to
pancreatic cancer from inception to invasion. Cancer Res 2007;67:9518–27.
982 Neesse A, et al. Gut 2014;63:974–983. doi:10.1136/gutjnl-2013-305559
Pancreatic cancer
7 Bayne LJ, Beatty GL, Jhala N, et al. Tumor-derived granulocyte-macrophage
colony-stimulating factor regulates myloid inﬂammation and T cell immunity in
pancreatic cancer. Cancer Cell 2012;21:822–35.
8 Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic
tumor formation. Cell 2012;148:349–61.
9 Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate
resistance to RAF inhibitors through HGF secretion. Nature 2012;487:500–4.
10 Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling
enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science
2009;324:1457–61.
11 Provenzano PP, Cuevas C, Chang AE, et al. Enzymatic targeting of the stroma
ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer
Cell 2012;21:418–29.
12 Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and
drug delivery in a mouse model of pancreatic cancer. Gut 2012;62:112–20.
13 Neesse A, Frese KK, Bapiro TE, et al. CTGF antagonism with mAb FG-3019
enhances chemotherapy response without increasing drug delivery in murine ductal
pancreas cancer. Proc Natl Acad Sci USA Published Online First: 8 July 2013.
doi:10.1073/pnas.1300415110
14 Mantoni TS, Schendel RR, Rodel F, et al. Stromal SPARC expression and patient
survival after chemoradiation for non-resectable pancreatic adenocarcinoma. Cancer
Biol Ther 2008;7:1806–15.
15 Infante JR, Matsubayashi H, Sato N, et al. Peritumoral ﬁbroblast SPARC expression
and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol
2007;25:319–25.
16 Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel
concentrations, and endothelial cell transport of cremophor-free, albumin-bound
paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res
2006;12:1317–24.
17 Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is
an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
J Clin Oncol 2011;29:4548–54.
18 Von Hoff DD, Ervin TJ, Arena FP, et al. Randomized phase III study of weekly
nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with
metastatic adenocarcinoma of the pancreas (MPACT). J Clin Oncol 2013;30(Suppl
34): abstr LBA148.
19 Frese KK, Neesse A, Cook N, et al. nab-Paclitaxel potentiates gemcitabine activity
by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.
Cancer Discovery 2012;2:260–9.
20 Hosein PJ, de Lima Lopes G, Pastorini VH, et al. A phase II trial of nab-Paclitaxel as
second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol
2013;36:151–6.
21 Desai NP, Trieu V, Hwang LY, et al. Improved effectiveness of nanoparticle
albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple
xenografts as a function of HER2 and SPARC status. Anticancer Drugs
2008;19:899–909.
22 Shao H, Tang H, Salavaggione OE, et al. Improved response to nab-paclitaxel
compared with cremophor-solubilized paclitaxel is independent of secreted protein
acidic and rich in cysteine expression in non-small cell lung cancer. J Thorac Oncol
2011;6:998–1005.
23 Desai N, Trieu V, Damascelli B, et al. SPARC expression correlates with tumor
response to albumin-bound paclitaxel in head and neck cancer patients. Transl
Oncol 2009;2:59–64.
24 Gilmour DT, Lyon GJ, Carlton MB, et al. Mice deﬁcient for the secreted glycoprotein
SPARC/osteonectin/BM40 develop normally but show severe age-onset cataract
formation and disruption of the lens. EMBO J 1998;17:1860–70.
25 Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to
promote chromosomal instability and widely metastatic pancreatic ductal
adenocarcinoma in mice. Cancer Cell 2005;7:469–83.
26 Freireich EJ, Gehan EA, Rall DP, et al. Quantitative comparison of toxicity of
anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer
Chemother Rep 1966;50:219–44.
27 Karreth FA, DeNicola GM, Winter SP, et al. C-Raf inhibits MAPK activation and
transformation by B-Raf(V600E). Mol Cell 2009;36:477–86.
28 Schellings MW, Vanhoutte D, Swinnen M, et al. Absence of SPARC results in
increased cardiac rupture and dysfunction after acute myocardial infarction. J Exp
Med 2009;206:113–23.
29 Arnold SA, Rivera LB, Miller AF, et al. Lack of host SPARC enhances vascular
function and tumor spread in an orthotopic murine model of pancreatic carcinoma.
Dis Model Mech 2010;3:57–72.
30 Stenner DD, Tracy RP, Riggs BL, et al. Human platelets contain and secrete
osteonectin, a major protein of mineralized bone. Proc Natl Acad Sci USA
1986;83:6892–6.
31 Sage H, Johnson C, Bornstein P. Characterization of a novel serum albumin-binding
glycoprotein secreted by endothelial cells in culture. J Biol Chem 1984;259:
3993–4007.
32 Tiruppathi C, Finnegan A, Malik AB. Isolation and characterization of a cell surface
albumin-binding protein from vascular endothelial cells. Proc Natl Acad Sci USA
1996;93:250–4.
33 Nozaki M, Sakurai E, Raisler BJ, et al. Loss of SPARC-mediated VEGFR-1
suppression after injury reveals a novel antiangiogenic activity of VEGF-A. J Clin
Invest 2006;116:422–9.
34 Rivera LB, Bradshaw AD, Brekken RA. The regulatory function of SPARC in vascular
biology. Cell Mol Life Sci 2011;68:3165–73.
35 Rivera LB, Brekken RA. SPARC promotes pericyte recruitment via inhibition of
endoglin-dependent TGF-beta1 activity. J Cell Biol 2011;193:1305–19.
36 Schnitzer JE, Oh P. Antibodies to SPARC inhibit albumin binding to SPARC, gp60,
and microvascular endothelium. Am J Physiol 1992;263:H1872–9.
Neesse A, et al. Gut 2014;63:974–983. doi:10.1136/gutjnl-2013-305559 983
Pancreatic cancer
